Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
28 05 2021
Historique:
received: 27 02 2021
accepted: 21 05 2021
entrez: 29 5 2021
pubmed: 30 5 2021
medline: 22 12 2021
Statut: epublish

Résumé

Soluble suppression of tumorigenesis-2 (sST2), Procollagen Type III N-Terminal Peptid (PIIINP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been verified their role in predicting survival in acutely decompensated heart failure (ADHF). However, whether their combination could improve more specific and sensitive prognostic information than NT-proBNP alone remains unclear. This was a prospective study, in which 217 ADHF patients at admission were enrolled from November 2018 and August 2019 (mean age 66.18 years ± 13.60, 63.98% male). The blood samples were collected to measure the concentrations of NT-proBNP, sST2 and PIIINP in the first 24 h of hospitalizations. All-cause mortality was registered for all patients after they were discharge over a median period of 339 days. In univariate Cox analysis, the three biomarkers were predictive of short-term mortality of ADHF patients. After adjusted for some clinical variables including age, admission systolic blood pressure, peripheral edema on admission, history of chronic obstructive pulmonary disease, admission sodium < 135 mmol/L, admission hemoglobin, NT-proBNP, sST2 and PIIINP was significantly associated with the poor outcome (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.14-1.53, P < 0.01; HR 1.21, 95% CI 1.03-1.43, P = 0.020; HR 1.40, 95% CI 1.08-1.81, P = 0.011). After added with Log2 PIIINP, but not Log2 sST2, the area under the curves (AUC) in the model of clinical variables and Log2 NT-proBNP could increase from 0.79 to 0.85 (95% CI 0.0071-0.10, P = 0.024). Furthermore, compared with the model of clinical variables, Log2 NT-proBNP, the improvement in the prognostic model of clinical variables, Log2 NT-proBNP and Log2 PIIINP had statistical significance [net reclassification improvement (NRI) 0.31, P = 0.018; integrated discrimination improvement (IDI) 0.068, P < 0.01]. NT-proBNP, sST2 and PIIINP are independent prognostic factors for all-cause mortality in ADHF patients. Furthermore, the combination of NT-proBNP and PIIINP may provide incremental prognostic value over NT-proBNP in the survival of ADHF patients.

Sections du résumé

BACKGROUND
Soluble suppression of tumorigenesis-2 (sST2), Procollagen Type III N-Terminal Peptid (PIIINP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been verified their role in predicting survival in acutely decompensated heart failure (ADHF). However, whether their combination could improve more specific and sensitive prognostic information than NT-proBNP alone remains unclear.
METHODS
This was a prospective study, in which 217 ADHF patients at admission were enrolled from November 2018 and August 2019 (mean age 66.18 years ± 13.60, 63.98% male). The blood samples were collected to measure the concentrations of NT-proBNP, sST2 and PIIINP in the first 24 h of hospitalizations. All-cause mortality was registered for all patients after they were discharge over a median period of 339 days.
RESULTS
In univariate Cox analysis, the three biomarkers were predictive of short-term mortality of ADHF patients. After adjusted for some clinical variables including age, admission systolic blood pressure, peripheral edema on admission, history of chronic obstructive pulmonary disease, admission sodium < 135 mmol/L, admission hemoglobin, NT-proBNP, sST2 and PIIINP was significantly associated with the poor outcome (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.14-1.53, P < 0.01; HR 1.21, 95% CI 1.03-1.43, P = 0.020; HR 1.40, 95% CI 1.08-1.81, P = 0.011). After added with Log2 PIIINP, but not Log2 sST2, the area under the curves (AUC) in the model of clinical variables and Log2 NT-proBNP could increase from 0.79 to 0.85 (95% CI 0.0071-0.10, P = 0.024). Furthermore, compared with the model of clinical variables, Log2 NT-proBNP, the improvement in the prognostic model of clinical variables, Log2 NT-proBNP and Log2 PIIINP had statistical significance [net reclassification improvement (NRI) 0.31, P = 0.018; integrated discrimination improvement (IDI) 0.068, P < 0.01].
CONCLUSIONS
NT-proBNP, sST2 and PIIINP are independent prognostic factors for all-cause mortality in ADHF patients. Furthermore, the combination of NT-proBNP and PIIINP may provide incremental prognostic value over NT-proBNP in the survival of ADHF patients.

Identifiants

pubmed: 34049488
doi: 10.1186/s12872-021-02083-6
pii: 10.1186/s12872-021-02083-6
pmc: PMC8164226
doi:

Substances chimiques

Biomarkers 0
IL1RL1 protein, human 0
Interleukin-1 Receptor-Like 1 Protein 0
Peptide Fragments 0
Procollagen 0
pro-brain natriuretic peptide (1-76) 0
procollagen Type III-N-terminal peptide 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

264

Références

Eur J Immunol. 2012 Jul;42(7):1863-9
pubmed: 22585662
Eur Heart J. 2014 Feb;35(7):419-25
pubmed: 24227810
J Am Heart Assoc. 2016 Aug 01;5(8):
pubmed: 27481133
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Am Coll Cardiol. 2008 Dec 16;52(25):2166-74
pubmed: 19095135
J Am Coll Cardiol. 2019 Mar 12;73(9):1016-1025
pubmed: 30846095
J Am Coll Cardiol. 2008 Oct 28;52(18):1458-65
pubmed: 19017513
Eur J Heart Fail. 2011 Jul;13(7):718-25
pubmed: 21551163
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
J Card Fail. 2010 Feb;16(2):128-34
pubmed: 20142024
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
JACC Heart Fail. 2014 Apr;2(2):148-58
pubmed: 24720923
Circ Heart Fail. 2009 Jul;2(4):311-9
pubmed: 19808354
J Card Fail. 2016 Sep;22(9):692-9
pubmed: 26721774
Am J Cardiol. 1995 May 1;75(14):913-8
pubmed: 7733000
Circulation. 2005 Nov 8;112(19):2940-5
pubmed: 16275882
Heart. 2014 Jan;100(2):115-25
pubmed: 24179162
Medicine (Baltimore). 2017 Apr;96(14):e6558
pubmed: 28383431
J Am Coll Cardiol. 2010 Jan 19;55(3):243-50
pubmed: 20117403
Int J Cardiol. 2013 Oct 3;168(3):2120-6
pubmed: 23395457
Front Physiol. 2018 Jun 26;9:758
pubmed: 29997521
Circ Heart Fail. 2018 Dec;11(12):e005488
pubmed: 30562096
Eur J Heart Fail. 2015 Aug;17(8):809-17
pubmed: 25921853
Growth Horm IGF Res. 2007 Aug;17(4):288-96
pubmed: 17383209
Int J Cardiovasc Imaging. 2017 Dec;33(12):1915-1920
pubmed: 28664478
J Am Coll Cardiol. 2004 May 5;43(9):1590-5
pubmed: 15120816
Eur Heart J. 2019 Oct 21;40(40):3345-3352
pubmed: 31093657
Circ Heart Fail. 2011 Sep;4(5):628-36
pubmed: 21743005
Clin Chim Acta. 2009 Nov;409(1-2):33-40
pubmed: 19699192
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
Am J Kidney Dis. 2003 Mar;41(3):571-9
pubmed: 12612980
Heart Fail Rev. 2014 Aug;19(4):453-70
pubmed: 25062653

Auteurs

Yiling Yao (Y)

Department of Cardiology, Zhongshan People Hospital, Sun Yat-Sen University, No. 2 Sunwen East Road, Zhongshan, 528400, Guangdong, People's Republic of China.

Li Feng (L)

Department of Cardiology, Zhongshan People Hospital, Sun Yat-Sen University, No. 2 Sunwen East Road, Zhongshan, 528400, Guangdong, People's Republic of China. fenglizssrmyy@126.com.

Yanxiang Sun (Y)

Department of Cardiology, Zhongshan People Hospital, Sun Yat-Sen University, No. 2 Sunwen East Road, Zhongshan, 528400, Guangdong, People's Republic of China.

Shifei Wang (S)

Department of Cardiology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.

Jie Sun (J)

Department of Cardiology, Zhongshan People Hospital, Sun Yat-Sen University, No. 2 Sunwen East Road, Zhongshan, 528400, Guangdong, People's Republic of China.

Bing Hu (B)

Department of Cardiology, Zhongshan People Hospital, Sun Yat-Sen University, No. 2 Sunwen East Road, Zhongshan, 528400, Guangdong, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH